Skip to content

The AMD Experts

teamphoto

Our Team

The MacuLogix team is committed to empowering primary eye care professionals with the technology and tools needed to create AMD Centers of Excellence®.

Bill McPhee, the President and CEO of MacuLogix, shares his personal story of why he joined the company and adopted its vision of eliminating blindness caused by AMD.

By being able to test more patients, we’ll ultimately uncover more macular degeneration. That’s good for patients. And I think we all need to realize is that what’s good for our patients winds up being good for our practices.

Jeffry D. Gerson, OD, FAAO Jeffry Gerson, OD, FAAO View all testimonials

Latest News & Upcoming Events

View More
Article: February 4, 2020 | Vision Monday

MacuLogix Intros Next Gen Dark Adaptation Function Testing

AdaptDx Pro guided by Theia is a new way to measure dark adaptation in a clinical setting quickly and effectively, using an objective, functional measurement called the Rod Intercept (RI).

Article: February 4, 2020 | Ophthalmology Web

AdaptDx Pro Guided by Theia Launched for Dark Adaptation Testing

The new AdaptDx Pro headset was custom-designed and tested for patient comfort and includes all the functionality and accuracy of the company’s table-top dark adaptometer.

Article: February 1, 2020 | Ophthalmology Management

Clinicians and Organizations Join Forces for AMD Awareness Month

Early detection makes increased awareness vital, experts say.

Put Our Expertise to Work

Testing with AdaptDx Pro

AdaptDx Pro identifies impaired dark adaptation—the earliest warning sign of AMD.

Implementation Expertise

Each AdaptDx Pro purchase is supported by our AMD Excellence Program™ to help you achieve your patient care and practice revenue goals.